Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials

Huang, Jiahao; Cao, Yunfei; Liao, Cun; Wu, Liucheng; Gao, Feng

doi:10.1186/cc9312

Critical Care

Table 1 Baseline characteristics of the trials

From: Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials

Study	Country	Study design	Duration	Follow-up	Treatment groups	APACHE II score	Patients			Intervention
							Number	Age, years	Males/Females
Prakash et al. [22], 2008	India	RCTs	_	7 days	Ranitidine	14.21 ± 5.44	25	35.1 ± 14.1	19/6	Ranitidine 50 mg, IV, every 6 hours
					Sucralfate	13.34 ± 6.03	25	27.5 ± 16.6	13/12	Sucralfate 1 g, every 6 hours
Kantorova et al. [23], 2004	Czech Republic	RCTs	Feb. 2000-June 2002	Until discharge or death	Famotidine	19.1 ± 9.3	71	47.0 ± 17	44/27	Famotidine 40 mg, IV, every 12 hours
					Sucralfate	18.8 ± 8.1	69	51.0 ± 18	50/19	Sucralfate 1 g, every 6 hours
Darlong et al. [24], 2003	India	RCTs	_	_	Ranitidine	_	24	44.0+18.5	11/13	Ranitidine 50 mg, IV, every 8 hours
					Sucralfate		21	39.5+15.2	14/7	Sucralfate 1 g, every 8 hours
Cook et al. [16], 1998	Canada	Multicenter RCTs	Oct. 1992-May 1996	Until discharge or death	Ranitidine	24.7 ± 7.1	596	58.8 ± 18.1	369/227	Ranitidine 50 mg, IV, every 8 hours
					Sucralfate	24.6 ± 7.3	604	58.7 ± 18.7	354/250	Sucralfate 1 g, every 6 hours
Thomason et al. [25], 1996	USA	RCTs	Nov. 1990-May 1994	27.3 days	Ranitidine	17.0	136	31.0	_	Ranitidine 150 mg/day, continuous IV
					Sucralfate	19.0	140	27.7	_	Sucralfate 1 g, every 6 hours
Prod'hom et al. [26], 1994	Switzerland	RCTs	Jan. 1989-Jan. 1991	_	Ranitidine	16.8 ± 8.6	80	52.2 ± 18.1	54/26	Ranitidine 150 mg/day, continuous IV
				_	Sucralfate	17.2 ± 8.6	83	46.4 ± 17.5	56/27	Sucralfate 1 g, every 4 hours
Pickworth et al. [27], 1993	USA	RCTs	Jan. 1989-Aug. 1991	Until discharge or death	Ranitidine	18.1 ± 6.5	44	27.3	60/23	Ranitidine 50 mg, IV, every 6 hours
					Sucralfate		39	26.8		Sucralfate 1 g, every 6 hours
Ruiz-Santana et al. [28], 1991	Spain	RCTs	Dec. 1998-Jan. 1990	Until discharge or death	Ranitidine	15 ± 5	19	39.0 ± 17	14/5	Ranitidine 50 mg, IV, every 6 hours
					Sucralfate		24	37.0 ± 18	20/4	Sucralfate 1 g, every 4 hours
Eddleston et al. [29], 1991	UK	RCTs	_	_	Ranitidine	12.4 ± 1.5	30	54.1 ± 3.1	17/13	Ranitidine 50 mg, IV, every 6 hours
			_	_	Sucralfate	11.6 ± 1.3	30	44.3 ± 3.5	21/9	Sucralfate 1 g, every 6 hours
Laggner et al. [30], 1989	Austria	RCTs	_	Until discharge or death	Ranitidine	_	16	60 ± 15	7/9	Ranitidine 50 mg, IV, every 4 hours
			_		Sucralfate	_	16	47 ± 19	11/5	Sucralfate 1 g, every 4 hours^a

The range of Acute Physiology and Chronic Health Evaluation II (APACHE II) scores was 0 to 71, with higher scores indicating a more severe
illness. ^aIf pH was less than 3.5, ranitidine 100 mg. IV, intravenous (injection); RCT, randomized controlled trial.

Back to article page

ISSN: 1364-8535

Contact us

Submission enquiries: journalsubmissions@springernature.com